Calls grow for changes to reporting of pharma R&D as PMPRB reports record drop
Canada's pharmaceutical industry is intensifying calls for the way its R&D spending is reported following the release of new data showing the largest one-year decline since 1988. The new data from the Patented Medicine Prices Review Board (PMPRB) show that pharmaceutical R&D expenditures in 2013 fell 15.
Other stories mentioning these organizations, people and topics
Other News
Events For Leaders in
Science, Tech, Innovation, and Policy
Discuss and learn from those in the know at our virtual and in-person events.
See Upcoming Events
You have 0 free articles remaining.
Don't miss out - start your free trial today.
Start your FREE trial Already a member? Log in
By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.